Spero Therapeutics schedules October 20 chat as target for Spero Therapeutics stock reaches USD 6.00

Published on 10/18/2026 at 13:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Spero Therapeutics will present on October 20 in New York. Spero Therapeutics stock has a USD 6.00 target after USD 5.00.

Conference plans and valuation context

Spero Therapeutics announced a New York conference appearance for October 20, 2026.
HC Wainwright raised its target from USD 5.00 to USD 6.00 on September 14, 2026.
Market capitalization stood at USD 64.1 million on October 16, 2026.

SPRO, US84833T1034, Illustration mit AI erstellt.

Spero Therapeutics (ISIN US84833T1034) will join the Chardan 10th Annual Healthcare Conference on October 20, while a USD 6.00 analyst target gives the stock a measurable valuation reference. According to Yahoo Finance on October 15, 2026, President and CEO Esther Rajavelu was scheduled to take part in a fireside chat in New York.

October 20 presentation sets the next date

The event is scheduled for October 20, 2026, with Spero leadership also available for one-on-one meetings. The company is a clinical-stage biopharmaceutical developer focused on immunology and inflammation, and its lead program SP001 is an Fc-silent anti-CD40L monoclonal antibody being advanced in IgG4-related disease, according to Spero Therapeutics.

What does the USD 6.00 target imply?

MarketBeat reported that HC Wainwright raised its price objective from USD 5.00 to USD 6.00 on September 14, 2026, while one analyst held a Buy rating and three held Hold ratings. The target therefore sits against a market value of USD 64.1 million reported for October 16, 2026.

Spero's recent chronology shows three distinct markers. On August 12, 2026, the company reported adjusted earnings per share of minus USD 0.16 against a minus USD 0.17 consensus estimate, according to Investing.com. On October 2, 2026, Spero announced 233,000 restricted stock units and 323,000 stock options for new employees, according to BioSpace. On October 15, 2026, it announced the conference appearance.

Dates investors can place on the calendar

The next substantiated company date is October 20, 2026, the Chardan conference presentation. The company calendar also lists November 12, 2026, as the next earnings date, but that date is labeled estimated by MarketBeat.

Market value remains the key reference

The Nasdaq-listed stock had a 52-week range of USD 1.08 to USD 3.08 on October 16, 2026, alongside a market capitalization of USD 64.1 million. The last euro quote stood at EUR 0.97 at Tradegate on October 16, 2026.

The further course of trading is shown by the continuously updated real-time quote of Spero Therapeutics stock.